Výsledky vyhledávání - "Meena Venkatachalam"

Akademický článek

An economic evaluation of nivolumab for the treatment of squamous and non-squamous NSCLC in the Swedish setting

Autor: Caitlin Smare, Meena Venkatachalam, Emma Medin, Marcus Hultberg, John R Penrod, Nadine Hertel, Michael Lees, Christoffer Holmberg

Publikováno v: Nordic Journal of Health Economics, Vol 7, Iss 1 (2019)

The cost-effectiveness of nivolumab versus docetaxel in patients with previously treated non-small cell lung cancer (NSCLC) was estimated in a cohort-based, partitioned survival model with three health states (progression-free, progressed disease, an

Externí odkaz: https://doaj.org/article/f643ce982bca4e41a7f3ac731d1b2599

Zobrazit plný text záznamu

Cost-Effectiveness of Cemiplimab Versus Standard of Care in the United States for First-Line Treatment of Advanced Non-small Cell Lung Cancer With Programmed Death-Ligand 1 Expression ≥50%

Autor: Emily Glowienka, Yingxin Xu, Florence Wilson, Patricia Guyot, Sam Keeping, Kokuvi Atsou, Meena Venkatachalam, Caitlin Smare, Chieh-I Chen, Andreas Kuznik, Gerasimos Konidaris, Keith Syson Chan

Publikováno v: Value in Health. 25:203-214

Objectives This study aimed to evaluate the cost-effectiveness, from a US commercial payer perspective, of cemiplimab versus other first-line treatments for advanced non-small cell lung cancer with programmed death-ligand 1 expression ≥50%. Methods

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e4ef31fe4b32e0c442797c60814540e
https://doi.org/10.1016/j.jval.2021.08.009

Zobrazit plný text záznamu

Cost-effectiveness of idecabtagene vicleucel compared with conventional care in triple-class exposed relapsed/refractory multiple myeloma patients in Canada and France

Autor: Korinna Karampampa, Wenjie Zhang, Meena Venkatachalam, Francois-Emery Cotte, Devender Dhanda

The chimeric antigen receptor (CAR) T-cell therapy idecabtagene vicleucel (ide-cel) is approved for the treatment of adult patients with relapsed/refractory multiple myeloma (RRMM) who have already received an immunomodulatory agent, a proteasome inh

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a3cc891384daad2680576aa190484be

Zobrazit plný text záznamu

Cost-effectiveness analysis of nivolumab for the treatment of squamous cell carcinoma of the head and neck in the United States

Autor: Meena Venkatachalam, Kate Young, James W. Shaw, Beata Korytowsky, Robert I. Haddad, Pranav Abraham, Ezra E.W. Cohen, Prianka Singh, Kevin J. Harrington

Publikováno v: Journal of medical economics. 23(5)

Aim: To assess the cost-effectiveness of nivolumab monotherapy for recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN) in the US. Methods: We constructed a cohort-based partitioned survival model for three health states (p

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1833313c66b1a83d7523c6936ec154c9
https://pubmed.ncbi.nlm.nih.gov/31928375

Zobrazit plný text záznamu

An economic evaluation of nivolumab for the treatment of squamous and non-squamous NSCLC in the Swedish setting

Autor: Marcus Hultberg, Christoffer Holmberg, Meena Venkatachalam, M Lees, John R. Penrod, Caitlin Smare, Emma Medin, N. Hertel

Publikováno v: Nordic Journal of Health Economics, Vol 7, Iss 1 (2019)
Nordic Journal of Health Economics (2020)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a97f1ed39d2a46325c2ee6cfb323a4f
https://journals.uio.no/NJHE/article/view/5453

Zobrazit plný text záznamu

Estimated costs of grade 3–4 all-cause and treatment-related adverse events for stage IV or recurrent non-small cell lung cancer (NSCLC) in the CheckMate 227 (CM-227) trial

Autor: Irene Santi, David D. Stenehjem, Komal Gupte-Singh, John R. Penrod, Meena Venkatachalam

Publikováno v: Journal of Clinical Oncology. 37:120-120

120 Background: In the ongoing phase 3 CM-227 trial, nivolumab + ipilimumab (N+I) showed significantly longer progression-free survival compared to chemotherapy (C) among patients with NSCLC and tumor mutational burden (TMB) ≥10 mutations/megabase

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::735c6ea7c998ee532f96858d26f4192f
https://doi.org/10.1200/jco.2019.37.8_suppl.120

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání